Announcement








                  Company Celltech Group PLC
                  TIDMCCH
                  Headline Further re offer for OGS
                  Released 12:06 24 Mar 2003
                  Number 1024J






NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA
OR JAPAN

24 March 2003
CELLTECH GROUP PLC ("CELLTECH")
CASH OFFER FOR OXFORD GLYCOSCIENCES PLC ("OGS")

Celltech notes the announcements this morning by OGS and CAT and confirms
that it has purchased approximately 10.5% of the issued share capital of
OGS at a price of 182 pence.
Celltech also notes that a holding of more than 10% of the shares to which
an offer relates would be sufficient to prevent the compulsory acquisition
provisions within the Companies Act from being implemented. This would be
relevant in the event of a competing bid for OGS implemented by way of an
offer under the City Code. However, Celltech further notes that approval
of a scheme of arrangement, as in the case of the CAT/OGS merger proposal,
would require the statutory majorities to be obtained. As a result the
shares currently held by Celltech would not prevent the CAT/OGS merger
proposal from proceeding should a majority in number of OGS shareholders
present and 75% of votes cast at the OGS Court Meeting be in favour of
the scheme. Based on the closing price of a CAT Share on 21 March 2003,
being the last business day prior to this announcement, the implied value
of OGS under the all paper CAT merger offer, is GBP85.7 million or 153.9
pence per OGS share. In comparison, the value of Celltech's all cash offer
is GBP101.4 million or 182 pence per OGS Share representing an additional
28.1 pence over the implied value of an OGS Share under the CAT merger
offer.

The first closing date for Celltech's offer for OGS is 31 March 2003.

Enquiries:
For further information contact:

      Celltech Group plcTelephone: +44 (0)1753 534 655
      Dr Peter Fellner, Chief Executive
      Peter Allen, Chief Financial Officer
      Richard Bungay, Director of Corporate Communications
      JPMorgan Telephone: +44 (0)20 7742 4000
      Bernard Taylor, Vice Chairman
      Julian Oakley, Managing Director
      Brunswick London Telephone: +44 (0)20 7404 5959
      Jon Coles
      Fiona Fong
      Brunswick New York Telephone: +1 212 333 3810
      Cindy Leggett-Flynn


Terms defined in the Offer Document have the same meaning when used in
this announcement.

Celltech and JPMorgan, acting on its behalf outside the United States,
are offering to purchase all of the issued and to be issued ordinary
shares of 5 pence each in OGS (including those represented by OGS ADSs)
at a price of 182 pence per OGS Share.

This announcement does not constitute an offer or invitation to purchase
any securities or a solicitation of an offer to buy any securities,
pursuant to the Offer or otherwise. The Offer is being made solely by the
Offer Document and the Acceptance Forms accompanying the Offer Document,
which contain the full terms and conditions of the Offer, including
details of how the Offer may be accepted. Celltech filed with the SEC a
Tender Offer Statement on Schedule TO containing the Offer Document and
other related information on 3 March 2003. Free copies of those
documents are available on the SEC's website at www.sec.gov. The Offer
 Document and the Acceptance Forms accompanying the Offer Document
have been made available to all OGS Securityholders at no charge to them.
OGS Securityholders are advised to read the Offer Document and the
accompanying Acceptance Forms which have been sent to them because they
contain important information. OGS Securityholders in the United States
are also advised to read the Tender Offer Statement because it contains
important information.  Unless otherwise determined by Celltech and
permitted by applicable law and regulation, the Offer (including the
Loan Note Alternative) is not being made, directly or indirectly, in or
into, or by use of the mails of, or by any other means or
instrumentality (including, without limitation, telephonically or
electronically) of interstate or foreign commerce of, or of any
facility of a national securities exchange of Canada, nor is it being
made in or into Australia or Japan and the Offer is not capable of
acceptance by any such use, means, instrumentality or facilities or
from within Australia, Canada or Japan. Accordingly, unless otherwise
determined by Celltech and permitted by applicable law and regulation,
neither copies of this announcement nor any other documents relating to
the Offer have been, or may be, mailed or otherwise forwarded,
distributed or sent in or into Australia, Canada or Japan and
persons receiving such documents (including custodians, nominees and
trustees) must not istribute or send them in, into or from such
jurisdictions.

The Loan Notes to be issued pursuant to the Loan Note Alternative
available under the Offer have not been, and will not be, listed on
any stock exchange and have not been and will not be registered under
the US Securities Act or under any relevant securities laws of any
state or other jurisdiction of the United States, or under the relevant
securities laws of Australia, Canada or Japan or any other jurisdiction.
Accordingly, unless an exemption under such relevant laws is available,
Loan Notes may not be offered, sold, re-sold or delivered, directly or
indirectly, in, into or from the United States, Australia, Canada or
Japan or any other jurisdiction in which an offer of Loan Notes would
constitute a violation of relevant laws or require registration of the
Loan Notes, or to or for the account or benefit of any US Person or
 resident of Australia, Canada or Japan or any other such jurisdiction.

THE OFFER WILL REMAIN OPEN FOR ACCEPTANCE DURING THE INITIAL OFFER PERIOD.
THE INITIAL OFFER PERIOD FOR ACCEPTANCES AND WITHDRAWALS WILL EXPIRE AT
3:00 P.M. (LONDON TIME), 10:00 A.M. (NEW YORK CITY TIME), ON 31 MARCH 2003,
UNLESS EXTENDED TO A LATER CLOSING DATE. AT THE CONCLUSION OF THE INITIAL
OFFER PERIOD, IF ALL CONDITIONS OF THE OFFER HAVE BEEN SATISFIED, FULFILLED
OR, WHERE PERMITTED, WAIVED, THE OFFER WILL BE EXTENDED FOR A SUBSEQUENT
OFFER PERIOD OF AT LEAST 14 CALENDAR DAYS. OGS SECURITYHOLDERS WILL HAVE
THE RIGHT TO WITHDRAW THEIR ACCEPTANCES OF THE OFFER FROM THE DATE OF
THIS ANNOUNCEMENT UNTIL THE SPECIFIED TIME ON THE LAST DAY OF THE INITIAL
OFFER PERIOD, BUT NOT DURING THE SUBSEQUENT OFFER PERIOD.

The Offer is conditional upon, among other things, valid acceptances being
received (and not, where permitted, being withdrawn) by 3:00 p.m. (London
time), 10:00 a.m. (New York City time) on 31 March 2003, or such later
time(s) and/or date(s) as Celltech may, subject to the City Code and in
accordance with the Exchange Act, decide in respect of not less than 90
percent (or such lesser percentage as Celltech may decide) of the OGS
Shares (including OGS Shares represented by OGS ADSs) to which the Offer
relates, provided that this condition will not be satisfied unless
Celltech shall have acquired, or agreed to acquire, pursuant to the Offer
or otherwise, OGS Shares (including OGS Shares represented by OGS ADSs)
carrying in aggregate more than 50 per cent of the voting rights normally
exercisable at a general meeting of OGS, including for this purpose (to
the extent, if any, required by the Panel) any voting rights attaching to
any OGS Shares (including OGS Shares represented by OGS ADSs) that are
unconditionally allotted or issued before the Offer becomes or is
declared unconditional as to acceptances pursuant to the exercise of
any outstanding subscription or conversion rights or otherwise.

Celltech reserves the right (but will not be obliged, other than as may
be required by the City Code or the Exchange Act) at any time or from time
to time to extend the Offer and, in such event, any decision to extend the
Offer will be publicly announced by 8:00 a.m. (London time) in the United
Kingdom and 8:00 a.m. (New York City time) in the United States on the day
(other than a Saturday or Sunday) following the day on which the Offer was
due to expire and which banks are generally open in London for normal
business. Except with the consent of the Panel, the Initial Offer Period
for acceptances and withdrawals may not extend beyond 1:00 p.m. (London
time), 8:00 a.m. (New York City time), on 30 April 2003.

The Directors of Celltech accept responsibility for the information
contained in this announcement, and, to the best of their knowledge and
belief (having taken all reasonable care to ensure such is the case), the
information contained in this announcement is in accordance with the facts
and does not omit anything likely to affect the import of such information.

J.P. Morgan plc, which is regulated in the United Kingdom by the Financial
Services Authority, is acting for Celltech and for no one else in
connection with the Offer and will not be responsible to anyone other than
Celltech for providing the protections afforded to customers of JPMorgan
or for providing advice in relation to the Offer, the contents of the Offer
Document or any transaction or arrangement referred to therein.

The Panel wishes to draw the attention of member firms of NASDAQ to certain
UK dealing disclosure requirements during the offer period. The offer
period (in accordance with the City Code, which is published and
administered by the Panel) commences at the time when an announcement is
made of a proposed or possible offer, with or without terms. OGS has
equity securities traded on the London Stock Exchange and NASDAQ.

The above disclosure requirements are set out in more detail in Rule 8 of
the City Code. In particular, Rule 8 requires public disclosure of dealings
during the offer period by persons who own or control, or who would as a
result of any transaction own or control, one per cent. or more of any
class of relevant securities of the offeree company. Relevant securities
include OGS Shares, OGS ADSs and instruments convertible into OGS Shares
or OGS ADSs. This requirement will apply until the first closing date or,
if this is later, the date when the Offer becomes or is declared
unconditional or lapses.

Disclosure should be made on an appropriate form by no later than 12 noon
(London time), 7 a.m. (New York City time) on the business day following
the date of the dealing transaction. These disclosures should be published
through a Regulatory Information Service.

The Panel requests that member firms advise those of their clients who wish
to deal in the relevant securities of OGS, whether in the United States or
in the United Kingdom, that they may be affected by these requirements. If
there is any doubt as to their application the Panel should be consulted
(telephone number: +44 (0) 20 7382 9026, fax number: +44 (0) 20 7638 1554).
This announcement has been approved by J.P.Morgan plc for the purpose of
section 21 of the Financial Services and Markets Act 2000 only.

END